PMID- 25011609
OWN - NLM
STAT- MEDLINE
DCOM- 20151028
LR  - 20240321
IS  - 2045-2322 (Electronic)
IS  - 2045-2322 (Linking)
VI  - 4
DP  - 2014 Jul 11
TI  - Tuning pharmacokinetics and biodistribution of a targeted drug delivery system 
      through incorporation of a passive targeting component.
PG  - 5669
LID - 10.1038/srep05669 [doi]
LID - 5669
AB  - Major challenges in the development of drug delivery systems (DDSs) have been the 
      short half-life, poor bioavailability, insufficient accumulation and penetration 
      of the DDSs into the tumor tissue. Understanding the pharmacokinetic (PK) 
      parameters of the DDS is essential to overcome these challenges. Herein we 
      investigate how surface chemistry affects the PK profile and organ distribution 
      of a gold nanoparticle-based DDS containing both a passive and active targeting 
      moiety via two common routes of administration: intravenous and intraperitoneal 
      injections. Using LC/MS/MS, ELISA and INAA we report the half-life, peak plasma 
      concentrations, area under the curve, ability to cross the peritoneal barrier and 
      biodistribution of the nanoconjugates. The results highlight the design criteria 
      for fine-tuning the PK parameters of a targeted drug delivery system that 
      exploits the benefits of both active and passive targeting.
FAU - Kudgus, Rachel A
AU  - Kudgus RA
AD  - Department of Oncology Research, Mayo Clinic, Rochester, Minnesota, United States 
      of America.
FAU - Walden, Chad A
AU  - Walden CA
AD  - Department of Oncology Research, Mayo Clinic, Rochester, Minnesota, United States 
      of America.
FAU - McGovern, Renee M
AU  - McGovern RM
AD  - Department of Oncology Research, Mayo Clinic, Rochester, Minnesota, United States 
      of America.
FAU - Reid, Joel M
AU  - Reid JM
AD  - Department of Oncology Research, Mayo Clinic, Rochester, Minnesota, United States 
      of America.
FAU - Robertson, J David
AU  - Robertson JD
AD  - Department of Chemistry and University of Missouri Research Reactor, University 
      of Missouri, Columbia, Missouri, United States of America.
FAU - Mukherjee, Priyabrata
AU  - Mukherjee P
AD  - Department of Pathology and Peggy and Charles Stephenson Cancer Center, 
      University of Oklahoma Health Science Center, Oklahoma City, OK, United States of 
      America.
LA  - eng
GR  - R01 CA135011/CA/NCI NIH HHS/United States
GR  - R01 CA136494/CA/NCI NIH HHS/United States
GR  - CA135011/CA/NCI NIH HHS/United States
GR  - CA136494/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20140711
PL  - England
TA  - Sci Rep
JT  - Scientific reports
JID - 101563288
RN  - 0 (Nanoconjugates)
RN  - 0 (Pharmaceutical Preparations)
RN  - 7440-57-5 (Gold)
SB  - IM
MH  - Animals
MH  - Area Under Curve
MH  - Drug Delivery Systems/methods
MH  - Gold/*administration & dosage
MH  - Half-Life
MH  - Male
MH  - Metal Nanoparticles/*administration & dosage
MH  - Mice
MH  - Nanoconjugates/*administration & dosage
MH  - Pharmaceutical Preparations/*administration & dosage/*metabolism
MH  - Tissue Distribution/*physiology
PMC - PMC4092331
EDAT- 2014/07/12 06:00
MHDA- 2015/10/29 06:00
PMCR- 2014/07/11
CRDT- 2014/07/12 06:00
PHST- 2014/04/30 00:00 [received]
PHST- 2014/06/25 00:00 [accepted]
PHST- 2014/07/12 06:00 [entrez]
PHST- 2014/07/12 06:00 [pubmed]
PHST- 2015/10/29 06:00 [medline]
PHST- 2014/07/11 00:00 [pmc-release]
AID - srep05669 [pii]
AID - 10.1038/srep05669 [doi]
PST - epublish
SO  - Sci Rep. 2014 Jul 11;4:5669. doi: 10.1038/srep05669.